Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 32

1.

Reports of atypical shoulder pain and dysfunction following inactivated influenza vaccine, Vaccine Adverse Event Reporting System (VAERS), 2010-2017.

Hibbs BF, Ng CS, Museru O, Moro PL, Marquez P, Woo EJ, Cano MV, Shimabukuro TT.

Vaccine. 2019 Nov 26. pii: S0264-410X(19)31546-4. doi: 10.1016/j.vaccine.2019.11.023. [Epub ahead of print]

PMID:
31784231
2.

Safety of the 9-Valent Human Papillomavirus Vaccine.

Shimabukuro TT, Su JR, Marquez PL, Mba-Jonas A, Arana JE, Cano MV.

Pediatrics. 2019 Dec;144(6). pii: e20191791. doi: 10.1542/peds.2019-1791. Epub 2019 Nov 18.

PMID:
31740500
3.

Inactivated influenza vaccine and spontaneous abortion in the Vaccine Safety Datalink in 2012-13, 2013-14, and 2014-15.

Donahue JG, Kieke BA, King JP, Mascola MA, Shimabukuro TT, DeStefano F, Hanson KE, McClure DL, Olaiya O, Glanz JM, Hechter RC, Irving SA, Jackson LA, Klein NP, Naleway AL, Weintraub ES, Belongia EA.

Vaccine. 2019 Oct 16;37(44):6673-6681. doi: 10.1016/j.vaccine.2019.09.035. Epub 2019 Sep 17.

4.

The MMR Vaccine and Autism.

DeStefano F, Shimabukuro TT.

Annu Rev Virol. 2019 Sep 29;6(1):585-600. doi: 10.1146/annurev-virology-092818-015515. Epub 2019 Apr 15.

PMID:
30986133
5.

Postlicensure Safety Surveillance of Recombinant Zoster Vaccine (Shingrix) - United States, October 2017-June 2018.

Hesse EM, Shimabukuro TT, Su JR, Hibbs BF, Dooling KL, Goud R, Lewis P, Ng CS, Cano MV.

MMWR Morb Mortal Wkly Rep. 2019 Feb 1;68(4):91-94. doi: 10.15585/mmwr.mm6804a4.

6.

Safety of bivalent human papillomavirus vaccine in the US vaccine adverse event reporting system (VAERS), 2009-2017.

Suragh TA, Lewis P, Arana J, Mba-Jonas A, Li R, Stewart B, Shimabukuro TT, Cano M.

Br J Clin Pharmacol. 2018 Dec;84(12):2928-2932. doi: 10.1111/bcp.13736. Epub 2018 Sep 21.

7.

Narcolepsy and adjuvanted pandemic influenza A (H1N1) 2009 vaccines - Multi-country assessment.

Weibel D, Sturkenboom M, Black S, de Ridder M, Dodd C, Bonhoeffer J, Vanrolleghem A, van der Maas N, Lammers GJ, Overeem S, Gentile A, Giglio N, Castellano V, Kwong JC, Murray BJ, Cauch-Dudek K, Juhasz D, Campitelli M, Datta AN, Kallweit U, Huang WT, Huang YS, Hsu CY, Chen HC, Giner-Soriano M, Morros R, Gaig C, Tió E, Perez-Vilar S, Diez-Domingo J, Puertas FJ, Svenson LW, Mahmud SM, Carleton B, Naus M, Arnheim-Dahlström L, Pedersen L, DeStefano F, Shimabukuro TT.

Vaccine. 2018 Oct 1;36(41):6202-6211. doi: 10.1016/j.vaccine.2018.08.008. Epub 2018 Aug 16.

8.

Notes from the Field: Vaccine Administration Errors Involving Recombinant Zoster Vaccine - United States, 2017-2018.

Shimabukuro TT, Miller ER, Strikas RA, Hibbs BF, Dooling K, Goud R, Cano MV.

MMWR Morb Mortal Wkly Rep. 2018 May 25;67(20):585-586. doi: 10.15585/mmwr.mm6720a4. No abstract available.

9.

Post-licensure safety surveillance of zoster vaccine live (Zostavax®) in the United States, Vaccine Adverse Event Reporting System (VAERS), 2006-2015.

Miller ER, Lewis P, Shimabukuro TT, Su J, Moro P, Woo EJ, Jankosky C, Cano M.

Hum Vaccin Immunother. 2018;14(8):1963-1969. doi: 10.1080/21645515.2018.1456598. Epub 2018 May 18.

10.

Post-licensure safety monitoring of quadrivalent human papillomavirus vaccine in the Vaccine Adverse Event Reporting System (VAERS), 2009-2015.

Arana JE, Harrington T, Cano M, Lewis P, Mba-Jonas A, Rongxia L, Stewart B, Markowitz LE, Shimabukuro TT.

Vaccine. 2018 Mar 20;36(13):1781-1788. doi: 10.1016/j.vaccine.2018.02.034. Epub 2018 Feb 21.

PMID:
29477308
11.

Safety of vaccines that have been kept outside of recommended temperatures: Reports to the Vaccine Adverse Event Reporting System (VAERS), 2008-2012.

Hibbs BF, Miller E, Shi J, Smith K, Lewis P, Shimabukuro TT.

Vaccine. 2018 Jan 25;36(4):553-558. doi: 10.1016/j.vaccine.2017.11.083. Epub 2017 Dec 14.

PMID:
29248264
12.

Reports of Postural Orthostatic Tachycardia Syndrome After Human Papillomavirus Vaccination in the Vaccine Adverse Event Reporting System.

Arana J, Mba-Jonas A, Jankosky C, Lewis P, Moro PL, Shimabukuro TT, Cano M.

J Adolesc Health. 2017 Nov;61(5):577-582. doi: 10.1016/j.jadohealth.2017.08.004.

PMID:
29061232
13.

Cognitive testing to evaluate revisions to the Vaccine Adverse Event Reporting System (VAERS) reporting form.

Suragh TA, Miller ER, Hibbs BF, Winiecki SK, Zinderman C, Shimabukuro TT.

Vaccine. 2017 Apr 25;35(18):2295-2297. doi: 10.1016/j.vaccine.2017.03.055. Epub 2017 Mar 25.

14.

Safety of Second-Dose Single-Antigen Varicella Vaccine.

Su JR, Leroy Z, Lewis PW, Haber P, Marin M, Leung J, Woo EJ, Shimabukuro TT.

Pediatrics. 2017 Mar;139(3). pii: e20162536. doi: 10.1542/peds.2016-2536. Epub 2017 Feb 7.

15.

Post-licensure safety surveillance of 23-valent pneumococcal polysaccharide vaccine in the Vaccine Adverse Event Reporting System (VAERS), 1990-2013.

Miller ER, Moro PL, Cano M, Lewis P, Bryant-Genevier M, Shimabukuro TT.

Vaccine. 2016 May 27;34(25):2841-6. doi: 10.1016/j.vaccine.2016.04.021. Epub 2016 Apr 15.

16.

Enhancing Vaccine Safety Capacity Globally: A Lifecycle Perspective.

Chen RT, Shimabukuro TT, Martin DB, Zuber PL, Weibel DM, Sturkenboom M.

Am J Prev Med. 2015 Dec;49(6 Suppl 4):S364-76. doi: 10.1016/j.amepre.2015.09.009. Review.

PMID:
26590436
17.
18.

Enhancing vaccine safety capacity globally: A lifecycle perspective.

Chen RT, Shimabukuro TT, Martin DB, Zuber PL, Weibel DM, Sturkenboom M.

Vaccine. 2015 Nov 27;33 Suppl 4:D46-54. doi: 10.1016/j.vaccine.2015.06.073. Epub 2015 Oct 1. Review.

19.

Vaccine Safety Resources for Nurses.

Miller ER, Shimabukuro TT, Hibbs BF, Moro PL, Broder KR, Vellozzi C.

Am J Nurs. 2015 Aug;115(8):55-8. doi: 10.1097/01.NAJ.0000470404.74424.ee. No abstract available.

20.

Safety monitoring in the Vaccine Adverse Event Reporting System (VAERS).

Shimabukuro TT, Nguyen M, Martin D, DeStefano F.

Vaccine. 2015 Aug 26;33(36):4398-405. doi: 10.1016/j.vaccine.2015.07.035. Epub 2015 Jul 22. Review.

21.

Deaths Reported to the Vaccine Adverse Event Reporting System, United States, 1997-2013.

Moro PL, Arana J, Cano M, Lewis P, Shimabukuro TT.

Clin Infect Dis. 2015 Sep 15;61(6):980-7. doi: 10.1093/cid/civ423. Epub 2015 May 28.

22.

Deaths following vaccination: What does the evidence show?

Miller ER, Moro PL, Cano M, Shimabukuro TT.

Vaccine. 2015 Jun 26;33(29):3288-92. doi: 10.1016/j.vaccine.2015.05.023. Epub 2015 May 23. Review.

23.

Vaccination errors reported to the Vaccine Adverse Event Reporting System, (VAERS) United States, 2000-2013.

Hibbs BF, Moro PL, Lewis P, Miller ER, Shimabukuro TT.

Vaccine. 2015 Jun 22;33(28):3171-8. doi: 10.1016/j.vaccine.2015.05.006. Epub 2015 May 14.

PMID:
25980429
24.

Post-licensure surveillance of quadrivalent live attenuated influenza vaccine United States, Vaccine Adverse Event Reporting System (VAERS), July 2013-June 2014.

Haber P, Moro PL, Cano M, Lewis P, Stewart B, Shimabukuro TT.

Vaccine. 2015 Apr 15;33(16):1987-92. doi: 10.1016/j.vaccine.2015.01.080. Epub 2015 Feb 9.

PMID:
25678241
25.

Adverse Events Following Measles, Mumps, and Rubella Vaccine in Adults Reported to the Vaccine Adverse Event Reporting System (VAERS), 2003-2013.

Sukumaran L, McNeil MM, Moro PL, Lewis PW, Winiecki SK, Shimabukuro TT.

Clin Infect Dis. 2015 May 15;60(10):e58-65. doi: 10.1093/cid/civ061. Epub 2015 Jan 30.

26.

Adverse events following Haemophilus influenzae type b vaccines in the Vaccine Adverse Event Reporting System, 1990-2013.

Moro PL, Jankosky C, Menschik D, Lewis P, Duffy J, Stewart B, Shimabukuro TT.

J Pediatr. 2015 Apr;166(4):992-7. doi: 10.1016/j.jpeds.2014.12.014. Epub 2015 Jan 15.

27.

Post-licensure surveillance of trivalent live attenuated influenza vaccine in adults, United States, Vaccine Adverse Event Reporting System (VAERS), July 2005-June 2013.

Haber P, Moro PL, McNeil MM, Lewis P, Woo EJ, Hughes H, Shimabukuro TT.

Vaccine. 2014 Nov 12;32(48):6499-504. doi: 10.1016/j.vaccine.2014.09.018. Epub 2014 Sep 22.

PMID:
25258101
28.

Incorporating research and evaluation into pandemic influenza vaccination preparedness and response.

Shimabukuro TT, Redd SC.

Emerg Infect Dis. 2014 Apr;20(4):713-714. No abstract available.

29.

Potential for improving age-appropriate vaccination coverage by maximizing the 18-month well-child visit.

Shimabukuro TT, Luman ET, Winston CA, Schieber RA.

J Public Health Manag Pract. 2007 Nov-Dec;13(6):572-7.

PMID:
17984710
30.

Medical expenditures for children with an autism spectrum disorder in a privately insured population.

Shimabukuro TT, Grosse SD, Rice C.

J Autism Dev Disord. 2008 Mar;38(3):546-52. Epub 2007 Aug 10.

PMID:
17690969
31.

Survey of state practices during the 2004-2005 influenza vaccine shortage.

Shimabukuro TT, Wortley PM, Bardenheier B, Bresnitz EA, DeBlois AM, Hahn CG, Mangione EJ.

Public Health Rep. 2007 May-Jun;122(3):311-8.

32.

Development and implementation of a nurse-managed anticoagulation program.

Shimabukuro TT, Kramer J, McGuire M.

J Healthc Qual. 2004 Jan-Feb;26(1):4-12; quiz 12-3.

PMID:
14763315

Supplemental Content

Loading ...
Support Center